Brooks Andrews joined EW in 2013 and is a Partner.
Mr. Andrews has more than 10 years of private equity investing experience. At EW, he is responsible for identifying and evaluating new investments across the healthcare sector including pharmaceutical, medical devices, diagnostic and technology-enabled service opportunities. He also plays an active role in the management and value creation process of existing portfolio companies.
Mr. Andrews currently serves on the Board of Directors of Sonendo and Xenex. He has also been a key member of the deal team in a number of the firm’s growth equity investments, including Axogen and EyePoint Pharma.
Prior to joining EW, Mr. Andrews was an Associate at Friedman Fleischer & Lowe (“FFL”), a growth-oriented private equity firm based in San Francisco. At FFL, he worked on several healthcare services investments ranging from IT to practice management to urgent care. Prior to FFL, Mr. Andrews worked at Barclay’s Capital in the firm’s investment banking division, focusing on financings, mergers and acquisitions in the communications and media industries.
Mr. Andrews received his Bachelor of Business Administration degrees in Economics and Finance and a Master of Arts degree in Economics from the University of Georgia, and a Master of Business Administration degree from Stanford University.